Total Valuation
Helus Pharma has a market cap or net worth of €1.22M. The enterprise value is €0.00.
Market Cap€1.22M
Enterprise Value€0.00
Share Statistics
Helus Pharma has 73,060,170 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding73,060,170
Owned by Insiders28.61%
Owned by Institutions<0.01%
Financial Efficiency
Helus Pharma’s return on equity (ROE) is -0.63 and return on invested capital (ROIC) is -60.93%.
Return on Equity (ROE)-0.63
Return on Assets (ROA)-0.58
Return on Invested Capital (ROIC)-60.93%
Return on Capital Employed (ROCE)-0.61
Revenue Per Employee-446.84K
Profits Per Employee-1.47M
Employee Count100
Asset Turnover-0.18
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Helus Pharma is ―. Helus Pharma’s PEG ratio is 0.16.
PE Ratio―
PS Ratio0.00
PB Ratio7.14
Price to FCF-16.39
Price to Operating Cash Flow-4.05
PEG Ratio0.16
Income Statement
In the last 12 months, Helus Pharma had revenue of -44.68M and earned -147.05M in profits. Earnings per share was -4.23.
Revenue-44.68M
Gross Profit-44.80M
Operating Income-141.68M
Pretax Income-57.69M
Net Income-147.05M
EBITDA-141.56M
Earnings Per Share (EPS)-4.23
Cash Flow
In the last 12 months, operating cash flow was -152.97M and capital expenditures -1.62M, giving a free cash flow of -154.59M billion.
Operating Cash Flow-152.97M
Free Cash Flow-154.59M
Free Cash Flow per Share-2.12
Dividends & Yields
Helus Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.34
52-Week Price Change124.03%
50-Day Moving Average10.61
200-Day Moving Average6.54
Relative Strength Index (RSI)52.29
Average Volume (3m)427.00
Important Dates
Helus Pharma upcoming earnings date is Nov 16, 2026, Before Open (Confirmed).
Last Earnings DateAug 14, 2026
Next Earnings DateNov 16, 2026
Ex-Dividend Date―
Financial Position
Helus Pharma as a current ratio of 9.52, with Debt / Equity ratio of 0.00%
Current Ratio9.52
Quick Ratio9.52
Debt to Market Cap0.00
Net Debt to EBITDA1.11
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Helus Pharma has paid 89.37M in taxes.
Income Tax89.37M
Effective Tax Rate-1.55
Enterprise Valuation
Helus Pharma EV to EBITDA ratio is -0.07, with an EV/FCF ratio of -0.07.
EV to Sales-0.21
EV to EBITDA-0.07
EV to Free Cash Flow-0.07
EV to Operating Cash Flow-0.07
Balance Sheet
Helus Pharma has €166.17M in cash and marketable securities with €40.19M in debt, giving a net cash position of €166.17M billion.
Cash & Marketable Securities€166.17M
Total Debt€40.19M
Net Cash€166.17M
Net Cash Per Share€2.27
Tangible Book Value Per Share€4.77
Margins
Gross margin is 0.00%, with operating margin of 317.06%, and net profit margin of 329.09%.
Gross Margin0.00%
Operating Margin317.06%
Pretax Margin129.09%
Net Profit Margin329.09%
EBITDA Margin316.79%
EBIT Margin317.06%
Analyst Forecast
The average price target for Helus Pharma is €36.65, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€36.65
Price Target Upside205.44% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast13.35%